Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Puxitatug Samrotecan?

Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct Cancer.

Sep 19, 2023 - 20:00
Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct Cancer.
Read the original article

Tags:

Previous Article

Pharmanovia announces acquisition of Sanofi’s CNS brands

Next Article

Risk adjusted net present value: What is the current valuation of Merck’s MK-0616?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: A young boy’s nightmare diagnosis, and the $3 million one-time treatment that will likely save his life

STAT+: A young boy’s nightmare diagnosis, and the $3 mi...

Apr 3, 2023

WHO says aspartame might cause cancer — but that most adult consumers don’t need to worry

WHO says aspartame might cause cancer — but that most a...

Jul 14, 2023

CDC recommends RSV monoclonal antibody for infants, high-risk young children

CDC recommends RSV monoclonal antibody for infants, hig...

Aug 3, 2023